

Biocon Ltd (BIOCON) - Financial and Strategic SWOT Analysis Review

<https://marketpublishers.com/r/B3FC36BBC60EN.html>

Date: July 2021

Pages: 68

Price: US\$ 125.00 (Single User License)

ID: B3FC36BBC60EN

Abstracts

Biocon Ltd (BIOCON) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company's businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company's key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:

Business description – A detailed description of the company's operations and business divisions.

Corporate strategy – Analyst's summarization of the company's business strategy.

SWOT Analysis – A detailed analysis of the company's strengths, weakness, opportunities and threats.

Company history – Progression of key events associated with the company.

Major products and services – A list of major products, services and brands of the company.

Key competitors – A list of key competitors to the company.

Key employees – A list of the key executives of the company.

Executive biographies – A brief summary of the executives' employment history.

Key operational heads – A list of personnel heading key departments/functions.

Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.

Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.

Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

Biocon Ltd (Biocon) is a biopharmaceutical company that focuses on the research and development of therapies for the treatment of chronic conditions such as cancer, diabetes and autoimmune diseases. It offers a wide range of active pharmaceutical ingredients (APIs), branded formulations, complex biologics and biosimilars including monoclonal antibodies (MAbs), rh-Insulin and insulin analogs. The company also provides services including contract manufacturing, drug licensing, research, development and manufacturing of small and large molecules for biotechnology and pharmaceutical companies across the world. It has a manufacturing facility and R&D centre at BioXcell, Malaysia. It operates overseas offices in the UK, Ireland, the US, Switzerland, Dubai and Malaysia. Biocon is headquartered in Bangalore, Karnataka, India.

Biocon Ltd Key Recent Developments

Jul 27,2021: Adagio and Biocon collaborate to develop antibody therapy for Covid-19

Jul 22,2021: Biocon Q1fy22 revenue at rs 1,808 cr, up 6%; EBITDA at rs 437 cr; biosimilars up 10 % at rs 758 cr; research services up 41 % at rs 595 cr;

Apr 28,2021: Biocon Q4FY21 Revenue at Rs 2,044 Cr, Up 26%; EBITDA at Rs 641 Cr; Up 68%

Mar 29,2021: Biocon Pharma partners with Libbs Farmaceutica to launch generic formulations in Brazil

Mar 02,2021: Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer for Emerging Markets

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.

The profile analyzes the company's business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors' business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.

The company's core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.

Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies' strategic, financial and operational performance.

Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.

Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

Contents

SECTION 1 - ABOUT THE COMPANY

Biocon Ltd - Key Facts
Biocon Ltd - Key Employees
Biocon Ltd - Key Employee Biographies
Biocon Ltd - Major Products and Services
Biocon Ltd - History
Biocon Ltd - Company Statement
Biocon Ltd - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture

SECTION 2 – COMPANY ANALYSIS

Company Overview
Biocon Ltd - Business Description
Business Segment: Biosimilars
Overview
Performance
Business Segment: Branded Formulations
Overview
Business Segment: Generics
Overview
Performance
Business Segment: Novel Biologics
Overview
Business Segment: Other Income
Performance
Business Segment: Research Services
Overview
Performance
Geographical Segment: India
Performance
Geographical Segment: Ireland
Performance
Geographical Segment: Rest of the world

Performance
Geographical Segment: The US
Performance
R&D Overview
Biocon Ltd - Corporate Strategy
Biocon Ltd - SWOT Analysis
SWOT Analysis - Overview
Biocon Ltd - Strengths
Biocon Ltd - Weaknesses
Biocon Ltd - Opportunities
Biocon Ltd - Threats
Biocon Ltd - Key Competitors

SECTION 3 – COMPANY FINANCIAL RATIOS

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts

SECTION 4 – COMPANY’S LIFESCIENCES, POWER FINANCIAL DEALS AND ALLIANCES

Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Biocon Ltd, Recent Deals Summary

SECTION 5 – COMPANY’S RECENT DEVELOPMENTS

Jul 27, 2021: Adagio and Biocon collaborate to develop antibody therapy for Covid-19
Jul 22, 2021: Biocon Q1fy22 revenue at rs 1,808 cr, up 6%; EBITDA at rs 437 cr; biosimilars up 10 % at rs 758 cr; research services up 41 % at rs 595 cr;
Apr 28, 2021: Biocon Q4FY21 Revenue at Rs 2,044 Cr, Up 26%; EBITDA at Rs 641 Cr; Up 68%
Mar 29, 2021: Biocon Pharma partners with Libbs Farmaceutica to launch generic formulations in Brazil
Mar 02, 2021: Biocon Biologics Appoints Susheel Umesh as Chief Commercial Officer

for Emerging Markets

Mar 01, 2021: Biocon Biologics promotes Shreehas Tambe to Deputy Chief Executive Officer

Jan 22, 2021: Biocon Q3fy21 revenue at ₹ 1,879 crore, up 7%; EBITDA at ₹427 crore; net profit at ₹169 crore; biosimilars up 11% at ₹769 crore; research services up 13% at ₹585 crore; generics down 3% at ₹561 crore

Oct 23, 2020: Biocon Q2fy21 revenue at rs 1,760 cr, up 10%; EBITDA at rs 407 cr; net profit (before exceptional item & discontinuing operations) at rs 174 cr; generics up 8% at rs 599 cr; biosimilars up 11% at rs 676 cr; research services up 12% at rs 520 cr.

Sep 22, 2020: Biocon appoints Anupam Jindal as its Chief Financial Officer

Jul 23, 2020: Biocon Q1FY21 revenue at Rs 1,690 Cr, Up 14%; EBITDA at Rs 432 Cr; Net Profit at Rs 153 Cr Generics up 16% at Rs 599 Cr, Biosimilars up 19% at Rs 692 Cr

SECTION 6 – APPENDIX

Methodology

Ratio Definitions

About GlobalData

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Biocon Ltd, Key Facts
Biocon Ltd, Key Employees
Biocon Ltd, Key Employee Biographies
Biocon Ltd, Major Products and Services
Biocon Ltd, History
Biocon Ltd, Other Locations
Biocon Ltd, Subsidiaries
Biocon Ltd, Joint Venture
Biocon Ltd, Key Competitors
Biocon Ltd, Ratios based on current share price
Biocon Ltd, Annual Ratios
Biocon Ltd, Annual Ratios (Cont...1)
Biocon Ltd, Annual Ratios (Cont...2)
Biocon Ltd, Interim Ratios
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021
Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Type, 2015 to YTD 2021
Biocon Ltd, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List Of Figures

LIST OF FIGURES

Biocon Ltd, Performance Chart (2017 - 2021)

Biocon Ltd, Ratio Charts

Biocon Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2015 to YTD 2021

Biocon Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2015 to YTD 2021

I would like to order

Product name: Biocon Ltd (BIOCON) - Financial and Strategic SWOT Analysis Review

Product link: <https://marketpublishers.com/r/B3FC36BBC60EN.html>

Price: US\$ 125.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B3FC36BBC60EN.html>